Prasinezumab

Phase 3Monoclonal antibody

Roche

Prasinezumab is one of 34 small molecule programs targeting Parkinson's Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson's DiseaseRecruiting

Parkinson's DiseasePhase 3

Recruiting

Competition

Competitive Landscape

53 competitors in Parkinson's Disease

#DrugCompanyPhaseTrials

Bendopa

MMerz North America, Inc.

Approved

13 2

Dayvigo

Eisai

Approved

1 3

Ingrezza

Neurocrine Biosciences

Hytrin

4 5

Strattera

MMap77

Phase 3

3 6

Glucophage

EMD Serono

Phase 3

3 7

Micardis

Boehringer Ingelheim

Phase 3

1 8

Plaquenil

Jazz Pharmaceuticals

Phase 2

1 9

Ketalar

AAultman Health Foundation

Phase 2

2 10

Coreg

Akero Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 2Not yet recruiting

Parkinson's Disease

NCT07055087

Phase 2Active, not recruiting

Parkinson's Disease

NCT04777331

Phase 3Recruiting

Parkinson's Disease

NCT07174310

Clinical

Trials by Indication[1]

Parkinson's Disease3 trials

Prevent Cognitive Decline in GBA-associated Parkinson's Disease

Not yet recruiting·UUniversity Hospital Tuebingen·Phase 2·NCT07055087·120 enrolled

A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

Active, not recruiting· Roche logo

Roche·Phase 2·NCT04777331·586 enrolled

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease

Recruiting· Roche logo

Roche·Phase 3·NCT07174310·900 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Prasinezumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prasinezumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prasinezumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Roche

Prasinezumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Parkinson's Disease3 trials

References

Drug Info

Quick Facts

Related News